The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 03, 2020
Filed:
Dec. 09, 2016
Applicant:
Carna Health Support Ltd., Fukuoka, JP;
Inventors:
Toyoshi Inoguchi, Fukuoka, JP;
Yasutaka Maeda, Fukuoka, JP;
Toshinobu Maki, Fukuoka, JP;
Noriyuki Sonoda, Fukuoka, JP;
Assignee:
CARNA HEALTH SUPPORT LTD., Fukuoka, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/7028 (2006.01); A61P 27/02 (2006.01); A61P 3/10 (2006.01); A61K 45/00 (2006.01); A61K 31/382 (2006.01); A61K 31/70 (2006.01); A61K 31/7042 (2006.01); A61K 31/7048 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7028 (2013.01); A61K 31/382 (2013.01); A61K 31/70 (2013.01); A61K 31/7042 (2013.01); A61K 31/7048 (2013.01); A61K 45/00 (2013.01); A61P 3/10 (2018.01); A61P 27/02 (2018.01);
Abstract
It is to provide an agent for treating and/or ameliorating retinopathy caused by glucose. It is an agent for treating retinopathy caused by glucose comprising sodium/glucose cotransporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, and is used at a normal dosage amount, or at a lower dosage whereby no lowering in blood sugar is observed.
Inoguchi, Toyoshi. (2020). Agent for treating retinopathy (U.S. Patent No. 10821126). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10821126
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile